Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults

We conducted a double-blind, placebo-controlled, parallel, dose-escalation trial to evaluate the pharmacokinetics and safety of single, oral doses of amprenavir (141W94; formerly VX-478), a potent inhibitor of human immunodeficiency virus (HIV) type 1 protease, administered as hard gelatin capsules...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Sadler, Brian M., Hanson, Cynthia D., Chittick, Gregory E., Symonds, William T., Roskell, Neil S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 1999
Gaiak:
Antiviral Agents
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC89344/
https://ncbi.nlm.nih.gov/pubmed/10390223
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak